Cargando…
Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications
Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability a...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429618/ https://www.ncbi.nlm.nih.gov/pubmed/34512356 http://dx.doi.org/10.3389/fphar.2021.731288 |
_version_ | 1783750566286983168 |
---|---|
author | Zhuang, Tongxi Li, Wei Yang, Li Wang, Zhengtao Ding, Lili Zhou, Mingmei |
author_facet | Zhuang, Tongxi Li, Wei Yang, Li Wang, Zhengtao Ding, Lili Zhou, Mingmei |
author_sort | Zhuang, Tongxi |
collection | PubMed |
description | Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability and degradable properties of ginsenosides in vivo, it should be admitted that the mechanism of ginsenosides on anti-obesity contribution is still obscure. Recently, studies have indicated that ginsenoside intervention has beneficial metabolic effects on obesity and its complications because it allows for the correction of gut microbiota dysbiosis and regulates the secretion of related endogenous metabolites. In this review, we summarize the role of gut microbiota in the pathogenetic process of obesity, and explore the mechanism of ginsenosides for ameliorating obesity, which can modulate the composition of gut microbiota by improving the metabolism of intestinal endogenous substances and alleviating the level of inflammation. Ginsenosides are expected to become a promising anti-obesity medical intervention in the foreseeable clinical settings. |
format | Online Article Text |
id | pubmed-8429618 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84296182021-09-11 Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications Zhuang, Tongxi Li, Wei Yang, Li Wang, Zhengtao Ding, Lili Zhou, Mingmei Front Pharmacol Pharmacology Obesity, generally characterized by excessive lipid accumulation, is a metabolic threat worldwide due to its rapid growth in global prevalence. Ginsenosides are crucial components derived from natural plants that can confer metabolic benefits for obese patients. Considering the low bioavailability and degradable properties of ginsenosides in vivo, it should be admitted that the mechanism of ginsenosides on anti-obesity contribution is still obscure. Recently, studies have indicated that ginsenoside intervention has beneficial metabolic effects on obesity and its complications because it allows for the correction of gut microbiota dysbiosis and regulates the secretion of related endogenous metabolites. In this review, we summarize the role of gut microbiota in the pathogenetic process of obesity, and explore the mechanism of ginsenosides for ameliorating obesity, which can modulate the composition of gut microbiota by improving the metabolism of intestinal endogenous substances and alleviating the level of inflammation. Ginsenosides are expected to become a promising anti-obesity medical intervention in the foreseeable clinical settings. Frontiers Media S.A. 2021-08-27 /pmc/articles/PMC8429618/ /pubmed/34512356 http://dx.doi.org/10.3389/fphar.2021.731288 Text en Copyright © 2021 Zhuang, Li, Yang, Wang, Ding and Zhou. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Pharmacology Zhuang, Tongxi Li, Wei Yang, Li Wang, Zhengtao Ding, Lili Zhou, Mingmei Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title | Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title_full | Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title_fullStr | Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title_full_unstemmed | Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title_short | Gut Microbiota: Novel Therapeutic Target of Ginsenosides for the Treatment of Obesity and Its Complications |
title_sort | gut microbiota: novel therapeutic target of ginsenosides for the treatment of obesity and its complications |
topic | Pharmacology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8429618/ https://www.ncbi.nlm.nih.gov/pubmed/34512356 http://dx.doi.org/10.3389/fphar.2021.731288 |
work_keys_str_mv | AT zhuangtongxi gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications AT liwei gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications AT yangli gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications AT wangzhengtao gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications AT dinglili gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications AT zhoumingmei gutmicrobiotanoveltherapeutictargetofginsenosidesforthetreatmentofobesityanditscomplications |